In a bid to help bring DMT and 5-MeO-DMT to patients, Biomind Labs has completed the development of its novel nasal gel delivery system.
Biotech company working with fast-acting psychedelics, Biomind Labs, has completed the development of its novel thermosensitive nasal gel delivery system for its DMT and 5-MeO-DMT product candidates.
The products are aimed at treating depression, anxiety, addictive disorders and eating disorders, and at improving the quality of life of patients suffering from neurodegenerative disorders.
Alejandro Antalich, CEO of Biomind Labs, commented: “We are pleased to announce that our scientific team has accomplished a major step in our molecule-to-market lifecycle by completing the development of a tailored drug delivery system for our DMT and 5-MeO-DMT product candidates.
“The delivery system has the potential to allow for a fast onset through easy administration as well as a potential decrease in side effects. It also has the potential to allow for decreased doses compared to the doses necessary to achieve similar results through other forms of systemic administration.
“Due to the seriousness of our targeted indications, we are committed to providing patients and the psychiatric community with novel pharmaceuticals that provide a comfortable, safe and efficient use.”
Biomind Labs said that the design of the gel consists of an adequate viscosity liquid, which turns into a mucoadhesive gel almost immediately after insertion into the nasal cavity upon contact with the mucosa at body temperature.
Earlier this year the company announced that its Phase II DMT clinical trial for treatment-resistant depression has been approved by the Brazilian Institutional Review Board, representing a “paramount step” in the company’s evolution, according to Antalich.
